SCHEMBL7547158

SCHEMBL7547158

COc1ccc(OC)c(C(CC2=NCCN2)c2ccccn2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 10/20 0.46
HTR1B P28222 1/20 0.45
MAOA P21397 4/20 0.43
MAOB P27338 4/20 0.43
ADRA1D P25100 3/20 0.40
ADRA1A P35348 3/20 0.40
ADRA1B P35368 3/20 0.40
ADRA2A P08913 2/20 0.40
ADRA2C P18825 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
PTGIR P43119 1/20 0.38
SYK P43405 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7553914 0.89 NISCH (0.46) NISCHHTR1BMAOAMAOBADRA1D
SCHEMBL7555007 0.89 NISCH (0.55) NISCHMAOAMAOBADRA1DADRA1A
SCHEMBL7554277 0.83 NISCH (0.50) NISCHHTR1BMAOAMAOBADRA1D
SCHEMBL7549185 0.83 NISCH (0.53) NISCHHTR1BMAOAMAOBADRA1D
SCHEMBL7546294 0.82 NISCH (0.52) NISCHHTR1BMAOAMAOBADRA1D
SCHEMBL7547088 0.79 NISCH (0.40) NISCHHTR1BMAOAMAOBADRA1D
SCHEMBL7547001 0.79 NISCH (0.49) NISCHHTR1BMAOAMAOBADRA1D
SCHEMBL7548321 0.79 NISCH (0.66) NISCHMAOAMAOBADRA1DADRA1A
SCHEMBL7548769 0.78 NISCH (0.51) NISCHMAOAMAOBADRA1DADRA1A
SCHEMBL7554011 0.77 NISCH (0.45) NISCHHTR1BMAOAMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US claimed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO claimed
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US disclosed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132812-A1 Oral hypoglycaemic agents SLC5A2, GPR119, SLC5A1 NISCH 448/4885HTR1B 3118/4885MAOA 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.